Introduction
Vasodilating agents are among the recommended first-line therapies in patients admitted for acute heart failure (AHF), 1 lack of evidence supporting their efficacy beyond the first hours of admission. 3 A drop in systolic blood pressure (SBP) during the first days of admission has been observed in several studies; 4 -6 however, the predictors of SBP decreases and the associations of such blood pressure (BP) decreases with outcomes were not reported in detail. An analysis of one small study did suggest that SBP reduction may be associated with untoward pathophysiological effects such as worsening of kidney function. 7 Such a potential deleterious effect of an SBP decrease may explain, at least in part, the results of some clinical studies in which pharmacologically induced SBP decreases led to deteriorations in renal function and subsequent adverse outcomes. 8 -10 This conclusion was strengthened by a recent analysis of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, which suggested that hypotension is relatively common during AHF hospitalization, and imposes a significant negative prognostic impact on 30-day outcomes. 11 In the current analysis, we assessed predictors of SBP changes at 24 h from study drug initiation (24-48 h from admission) and their associations with worsening kidney function and clinical outcomes in the Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies (VERITAS). 4 ,5
Methods
The VERITAS project comprised two identical, concurrent randomized trials that evaluated the efficacy of tezosentan administration within 24 h of hospital presentation for AHF. 4, 5 Inclusion criteria required patients to have reported dyspnoea at rest after receipt of i.v. diuretics and to have at least two of four objective signs of heart failure (HF): elevated natriuretic peptides; pulmonary oedema on physical examination; pulmonary congestion or oedema on chest X-ray, and left ventricular systolic dysfunction evidenced by reduced ejection fraction or wall motion index. Patients with SBP of ≤100 mmHg, or ≤120 mmHg if receiving a vasodilator, were excluded. Patients enrolled in error more than 24 h after presentation and patients without a measured SBP at 24 h were also excluded from the analyses.
Routine laboratory measurements at baseline, 24 h and 72 h were obtained locally, whereas troponin I and brain natriuretic peptide levels were assayed centrally. Patients were followed for worsening HF for 30 days, and vital status was assessed at 6 months.
Statistical analysis
Summary statistics are reported as the mean and standard deviation for continuous variables, and as the median (interquartile range) for skewed variables; proportions in each category are presented for categorical variables. Patients were grouped by tertiles of the change in SBP from baseline to 24 h and baseline characteristics were compared using analysis of variance (ANOVA) or Cochran-Mantel-Haenszel 2 tests, as appropriate.
Linear regression was used to model the associations of baseline characteristics with the change in SBP from baseline to 24 h. Non-linearity of the association between each continuous variable and SBP change was assessed by testing the contribution of the non-linear terms of a restricted cubic spline transformation with four knots. A linear spline, quadratric or cubic polynomial, or log transformation, was chosen, based on the Akaike's information criterion, to model non-linear associations. Ten multiple imputation datasets assuming multivariate normality were used for missing baseline covariates, 12 and parameter estimates were averaged over these imputation datasets using Rubin's algorithm. 13 A multivariable model was selected in each imputation dataset from among the baseline characteristics using backward elimination with a retention criterion of P < 0. included those covariates included in at least six of the 10 imputation datasets. The unadjusted association of SBP change at 24 h with creatinine change at 72 h was assessed using linear regression. Logistic regression was used to provide the odds ratios for the association between SBP change at 24 h and an increase in creatinine of ≥0.3 mg/dL at 72 h, with covariates for multivariable adjustment selected using the methodology described above.
Associations between the SBP changes and 30-day all-cause death or HF readmission, and 180-day all-cause death, were examined using Cox proportional hazards models. Potential confounding was addressed through multivariable adjustment for baseline SBP and covariates previously found to be prognostic of these outcomes.
14 SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA) was used for all analyses.
Results
Of the 1449 patients randomized, 102 patients were enrolled at more than 24 h from presentation and 90 patients lacked data on the change in SBP at 24 h. These patients were excluded from the dataset, leaving 1257 patients for analysis.
Patients' baseline characteristics by tertiles of SBP change at 24 h are presented in Table 1 . Unadjusted and multivariable-adjusted associations between baseline characteristics and SBP decrease at 24 h are presented in Table 2 . Predictors of a larger SBP drop at 24 h were lack of atrial fibrillation or diabetes mellitus, higher baseline SBP, longer QRS interval, higher blood urea nitrogen (BUN), and lower white blood cell count. Respiratory rate, heart rate and creatinine had non-linear relationships with SBP change. Tezosentan treatment was associated with a larger mean SBP decrease at 24 h [mean difference 6.17, 95% confidence interval (CI) 4.39-7.96; P < 0.001].
Change in SBP at 24 h was inversely associated with change in creatinine at 72 h ( Figure 1) . The relationship had an inflection point around −15 mmHg; that is, SBP decreases of >15 mmHg were associated with a numerical acceleration in creatinine increase, although the departure from non-linearity was not statistically significant (P = 0.5910). The percent is out of subjects in the analysis population with non-missing creatinine change at day 3. 222/1068 (20.8%) had a creatinine change of ≥0.3 mg/dL at 72 h. Patients with larger decreases in SBP at 24 h were more likely to have a creatinine change of ≥0.3 mg/dL at 72 h [odds ratio (OR) per 1 mmHg greater decrease in SBP: 1.01, 95% CI 1.00-1.02; P = 0.0272]. The association of SBP change with creatinine increase did not differ significantly by tezosentan treatment (interaction P = 0.7239). After multivariable adjustment for factors found to be associated with a creatinine change of ≥0.3 mg/dL at 72 h in the VERITAS database (supplementary material online, Table S1 ) [age, renal impairment, time from admission to randomization, respiratory rate and estimated glomerular filtration rate (eGFR)], the association of SBP change with a creatinine change of ≥0.3 mg/dL was of borderline statistical significance (OR per 1 mmHg decrease in SBP: 1.01, 95% CI 1.00-1.01; P = 0.0941). Tezosentan treatment was not significantly associated with the risk for a creatinine increase of ≥0.3 mg/dL, and further adjustment for tezosentan treatment did not affect the association of SBP change with outcome. Similarly, SBP decrease at 24 h was associated with a greater risk for adverse outcomes at both 30 days and 180 days. All-cause death, worsening HF or HF readmission within 30 days occurred in 395 of 1257 (31.4%) patients and 165 of 1257 (13.1%) patients died within 180 days. After multivariable adjustment, the hazard ratio (HR) for each 1 mmHg decrease in SBP at 24 h for 30-day death, worsening HF or HF rehospitalization was 1.01 (95% CI 1.00-1.02; P = 0.021), and this association did not differ by randomized treatment (interaction P = 0.3409). A larger decrease at 24 h in SBP was also associated with an increased risk for all-cause mortality at 180 days. age, heart rate, respiratory rate, history of chronic HF, history of diabetes, history of chronic obstructive pulmonary disease (COPD), SBP, renal impairment, baseline score for dyspnoea on a visual analogue scale (VAS), albumin, BUN, haemoglobin and sodium.
14 For 180-day all-cause death, covariates for multivariable adjustment were age, heart rate, history of ischaemic heart disease, peripheral vascular disease or stroke, SBP, baseline dyspnoea VAS, history of COPD, albumin, BUN, white blood cell count and sodium.
14 After multivariable adjustment, the HR for each 1 mmHg decrease in SBP at 24 h for 180-day all-cause mortality was 1.01 (95% CI 1.00-1.03; P = 0.038). There was no interaction between SBP decrease and outcomes in tezosentan-treated vs. placebo-treated patients (interaction P = 0.1414). Figure 2 depicts the association between 180-day mortality and SBP decrease at different time-points to 24 h and suggests a lack of significance in the first 12 h and an increased effect of SBP decrease with time.
Discussion
The present analysis of VERITAS data suggests an inverse correlation between SBP changes and renal function as measured by creatinine changes at 72 h, as well as 30-and 180-day outcomes in patients with AHF. Patients with larger decreases in BP were especially prone to creatinine increases, as well as increased risk . for 30-day death, worsening HF or HF readmission, and 180-day mortality.
The results of these analyses are largely in line with those of previous studies, and both confirm and supplement them. In a small analysis of the Pre-RELAX-AHF (Relaxin in Acute Heart Failure) Phase 2 study, Voors et al. 7 showed that BP decrease is associated with renal function deterioration. An analysis of the larger ASCEND-HF study 11 demonstrated that hypotension, strictly defined as an SBP decrease to <90 mmHg regardless of initial BP, was associated with increased risk for adverse outcome at 30 days, but not with renal impairment at day 10 or discharge. As the restrictions imposed by the selection of the subgroup analysed in ASCEND-HF (i.e. patients with hypotension defined by a specific cut-off and assessment of renal function distant from the event) limit the analysis to a specific subgroup of patients, it is possible that a relative decrease in SBP rather than the reaching of an arbitrary threshold is more important prognostically. Indeed, in the present analysis, baseline-adjusted SBP decreases were associated both with more adverse outcomes and with more renal impairment, regardless of the magnitude of decrease in SBP.
The relationship between SBP changes and outcomes after treatment with vasodilating agents has not been thoroughly studied in the past. In the current analysis, no interaction was found between SBP decrease, drug therapy and outcomes (P = 0.1414 for 180-day mortality), although, as noted previously, active therapy with tezosentan was associated with a greater decrease in SBP. Thus, the increased risk associated with a larger drop in SBP may have neutralized the beneficial effects of the new treatment.
Previous studies have suggested that such SBP lowering induced by active interventions may lead to more adverse outcomes. In earlier studies, in which doses of nesiritide higher than those given in ASCEND-HF were administered, nesiritide therapy led to more hypotension, renal impairment and increased mortality. 9 However, this finding was not replicated in the ASCEND-HF study, in which lower doses of nesiritide were administered. In the REVIVE study, similar findings were reported and greater hypotension in the active arm was associated with a trend towards earlier mortality, 8 especially in patients enrolled with lower BP at screening. Finally, in the recently reported TRUE-AHF study, administration of ularitide was associated with a greater SBP decrease in the active arm (approximately 10 mmHg at 24 h), an increase in creatinine and a numerical increase in early mortality at 180-240 days.
10 These results can be explained by some negative effects of BP decreases on perfusion in end organs such as kidneys, 7 although data on the mechanism behind why such decreases in BP may be detrimental are not available. These findings may underestimate the true negative effects of BP reduction in AHF as creatinine is not a perfect measure of kidney dysfunction. 15 Further, no studies examining the effects of agents with vasodilating effects have ever demonstrated beneficial effects in patients with AHF beyond the first few hours of admission. Most importantly, the effects of administration of i.v. nitrates beyond the first 1-2 h of admission have never been examined in detail, although these agents are recommended in guidelines for the treatment of AHF.
1 Interestingly, the present data also show that early changes in SBP have no relationship with outcomes, whereas changes that occur beyond 12 h from admission are associated with worse outcomes. Hence, the totality of the evidence -in both the current and previous analyses, as well as prospective studies -begs the question of whether vasodilation, long held as a pillar of therapy for AHF, does indeed benefit patients beyond the first hours of administration, especially once normal SBP values are reached. These data would suggest that our knowledge of the effects of vasodilation in AHF is incomplete and studies to examine such effects may be urgently needed. In the meantime, physicians should exercise caution when administering vasodilating agents to patients with AHF, especially when they cause a significant reduction in SBP of >15-25 mmHg or when a low SBP is reached.
Limitations
The current analysis is a post hoc analysis of data from the VERITAS project and as such should be seen as hypothesis-generating and not as definitive.
Conclusions
Systolic blood pressure decreases in patients with AHF are associated with more early renal impairment and an increase in adverse outcomes at 30 and 180 days. Studies examining the effects of vasodilating agents such as i.v. nitrates in AHF are urgently needed and, until such studies are performed, caution should be exercised in the administration of these agents to patients with AHF, especially when significant falls in SBP are observed.
Supplementary Information
Additional Supporting Information may be found in the online version of this article: Table S1 . Multivariable associations of baseline characteristics with creatinine change of ≥0.3 mg/dL at 72 h.
